KT 6352
Latest Information Update: 19 Dec 2006
Price :
$50 *
At a glance
- Originator Kyowa Hakko
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 25 Aug 1999 Preclinical development for Thrombocytopenia in Japan (Unknown route)